AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as in vivo models resistant to KRAS G12C inhibitors.
4984_Integrated platform enables KRAS-targeted drugs discovery_final - Copy
Related Content
STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation. STATs are known to play a role in...
VIEW RESOURCEAt the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...
VIEW RESOURCE